An method and formulation are provided for the prevention and treatment of
adverse ocular conditions which are complications of diabetes. In one
embodiment, the invention comprises administering to a person having
diabetes, insulin resistance, or a risk factor for diabetes a formulation
comprising a metal chelator and a transport enhancer. Most preferably,
the metal chelator is EDTA or a salt of EDTA, and the transport enhancer
is methylsulfonylmethane (MSM). The formulation may be in a form suitable
for application to the eye itself, for example, in the form of eye drops.